Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung

Publikation

Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung

Wissenschaftlicher Artikel/Review - 15.06.2016

Reichegger Hermann, Jochum Wolfram, Förbs Diana, Hader Claudia, Früh Martin

Zitation

Reichegger H, Jochum W, Förbs D, Hader C, Früh M. Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung. Oncol Res Treat 2016; 39:461-3.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Oncol Res Treat 2016; 39

Veröffentlichungsdatum

15.06.2016

eISSN (Online)

2296-5262

Seiten

461-3

Kurzbeschreibung/Zielsetzung

BACKGROUND
Osimertinib (AZD9291, Tagrisso) is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).

CASE REPORT
Our report demonstrates that osimertinib is able to inhibit the growth of a radiotherapy- and surgery-refractory EGFR T790M-positive brain metastasis in a patient with lung adenocarcinoma.

CONCLUSION
These data show that re-biopsy in EGFR-mutated non-small cell lung cancer patients with acquired TKI resistance should be performed.